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Abstract 
We report the experience from the Antiphospholipid Antibodies (aPL) Regional Consortium in northwest Italy, 
meant to support clinical research and foster collaboration among health professionals regarding the 
diagnosis and management of antiphospholipid syndrome (APS) patients. This cohort-study (APS Piedmont 
Cohort) was designed to register the clinical characteristics at inception and associated immunological 
manifestations at diagnosis (if any) of patients who strictly fulfilled the current criteria for APS, all recruited at 
the Piedmont and Valle d'Aosta regions. 
Clinical and laboratory data from 217 APS patients (171 with vascular events, 33 with pregnancy morbidity 
and 13 with both), from 16 centres within the geographical area were collected. Venous thrombosis was 
recorded in 45.6% of patients, arterial thrombosis in 35%, small-vessel thrombosis in 1.12% and mixed 
arterial and venous thrombosis in the remaining 19.4% of the cases. Pregnancy morbidity included 19 
patients with unexplained fetal death beyond the 10th week of pregnancy, 17 with premature birth before the 
34th week and 10 with three or more unexplained spontaneous abortions before the 10th week of gestation. 
This consortium represents an instrument by which to audit clinical practice, to provide counselling to local 
centres and to sustain future basic and clinical APS research. 
 
 
 
 
Introduction 
Seven years ago, in 2004, a consortium dedicated to the study of antiphospholipid syndrome (APS) began 
its activity in the Piedmont and Valle D'Aosta regions. The APS Piedmont Consortium is part of the Rare 
Diseases Network of the Italian National Health System Service. The main objective of this study is to 
describe the clinical characteristics at presentation and the associated immunological manifestations at 
diagnosis (if any) in patients who strictly fulfilled the updated classification criteria for APS.1 All patients were 
enrolled in the Interregional Register of Rare Diseases as part of the National Health System Service. The 
second aim is to compare the characteristics of our cohort to other published studies, mainly to the Euro-
Phospholipid cohort.2 This consortium is worthy of interest for at least three reasons: (1) all patients were 
diagnosed and enrolled after a strict selection, according to well-established classification criteria, (2) all 
patients live in a well-defined geographical area and (3) all participating laboratories undergo periodically an 
external quality assessment (EQA) to ascertain their performance. 
Patients and methods 
 
APS Piedmont Consortium 
The APS Piedmont Consortium is a group of physicians and biologists from different specialties, working in 
the Piedmont and Valle d’Aosta regions, an area of about 5 million inhabitants.The main aims of the 
consortium were: (1) to collect and record data at diagnosis, (2) to improve knowledge on diagnosis and 
management in the area, (3) to share current diagnostic and therapeutic strategies, (4) to discuss 
controversial clinical cases and (5) to support clinical and laboratory research in the field of APS. 
Patient selection 
The Piedmont Cohort includes 217 consecutive patients, selected from a wider group of about 400 
suspected APS patients. All the enrolled patients strictly met the current classification criteria for APS.1 All 
cases diagnosed before 2006 were revised for Sydney criteria compliance. Patients were registered in a 
database program (Excel) for a scheduled follow-up visit in a tertiary hospital or university department. Data 
included in the database comprised: (1) gender, (2) race, (3) age at diagnosis, (4) underlying autoimmune 
disease, if any, (5) clinical manifestations at onset (defined as index event) and (6) laboratory profile. 
Conventional cardiovascular risk factors (including smoking, hypertension, hypercholesterolaemia, diabetes 
and family history of thrombosis), ongoing therapy before and after disease onset/relapse, and screening for 
inherited thrombophilia (when performed) were also registered.The study was performed according to the 
principles of the Declaration of Helsinki, and written consent was sought at the time of inclusion in the 
Interregional Register of Rare Disease — National Health System Service. 
Laboratory studies 
IgG and IgM anticardiolipin antibodies (aCL) and anti- β 2 glycoprotein-I (anti-β2GPI) were measured using 
different commercially available ELISA kits according to the proposal of the Standardization Group of the 
European Forum on Antiphospholipid Antibodies (aPL).3 The results of the aCL testing were expressed in 
GPL (1 unit IgG phospholipid) or MPL (1 unit IgM phospholipid) and those of anti-β2GPI in arbitrary units 
(U/ml), in accordance with the Sydney updated classification criteria.1 The cut-off values for medium/high 
titres for aCL were 40 GPL or MPL. Cut-off values for anti-β2GPI were calculated by the 99th percentile of 
healthy subjects. Lupus anticoagulant (LA) was tested according to the revised International Society on 
Thrombosis and Haemostasis (ISTH) three-step diagnostic strategy.4 
Statistical analysis was performed by using SPSS 16.0 (Microsoft software). Two-sample t-tests, χ2 test and 
Fisher’s exact tests were used for comparisons of continuous and categorical measures, as appropriate. 
 
Results 
General characteristics and index events from the Piedmont Cohort compared to the Euro-Phospholipid 
Cohort are shown in Table 1. Overall, 102 patients were diagnosed as having APS associated with other 
autoimmune diseases, such as systemic lupus erythematosus (SLE) (27.6%), undifferentiated connective 
tissue disease (UCTD) (7.3%) and other diseases (11.9%). The median age at diagnosis was 42 (range 13–
80 years; mean 43.71 ± 15.31). In primary APS mean age at diagnosis was significantly higher when 
compared to all the cases (46.54 ± 15.9 vs. 41.13 ± 13.88, p = 0.0034). The presence of more than two 
conventional risk factors for thrombosis was significantly higher in patients with vascular APS compared to 
the ones who experienced pregnancy morbidity (odds ratio (OR) = 3.01 [95% confidence interval (CI) 1.7–
6.7], p = 0.041). Low-risk inherited thrombophilic defects showed no difference in prevalence in the 
thrombotic vs. the obstetric subgroup. For 46 patients (21.2% of the Piedmont Cohort) the index event was a 
pregnancy morbidity; 99 (45.6%) had venous thromboembolism and 76 (35%) had arterial thrombosis. 
Laboratory results and the prevalence of the different aPL are shown in Table 2. Out of the 217 patients, 108 
(49.8%) patients had more than one aPL detected (laboratory profile 1, according to Miyakis' criteria).1 Of 
these 108 patients, 54 exhibited a triple positivity. Furthermore, LA positivity was the most frequent aPL 
finding in this cohort (44.2%), an overall prevalence much higher than the 12.1% reported by the Euro-
Phospholipid Cohort.2 Miyakis type 1 and 2a profiles together represented more than 93% of all APS cases; 
24.9% of patients displayed triple aPL positivity. Pregnancy morbidity was the index event in 46 patients, 
including 19 patients with unexplained fetal deaths beyond the 10th week, 17 with premature birth before the 
34th week and 10 with three or more unexplained spontaneous abortions before the 10th week. 
 Discussion 
The Piedmont Cohort is a group of strictly selected APS patients classified according to ongoing clinical and 
laboratory criteria, all coming from a well-defined geographical area in northwest Italy and tested at EQA-
compliant laboratories. Although a comparison with the Euro-Phospholipid Project (EURO-APS), published 
in 2002, was attempted, many differences attributed to the classification criteria used at the time of the 
diagnosis/inclusion in the cohort were found.2 In particular, in the EURO-APS cohort: (1) laboratory 
screening was performed using only two tests (aCL and LA), (2) tests were considered positive if aCL was 
above 20 GPL/MPL and were repeated after six weeks and (3) clinical manifestations such as transitory 
ischemic attacks (TIAs), superficial thrombophlebitis and thrombocytopaenia were also included. However, 
age, sex distribution at diagnosis and primary APS prevalence were similar between the cohorts, even 
though a female predominance was observed in previous APS series.2,6 In our cohort, we observed a 
higher prevalence of arterial thrombotic events (stroke plus acute myocardial infarction (AMI)) and fetal 
losses when compared to the EURO-APS. Concerning the aPL profile, higher risk patients are represented 
in the Piedmont Cohort when compared to the EURO-APS. In the Piedmont Cohort, more than 90% of 
patients had Miyakis type 1 or 2a aPL profile,1 among whom 25% displayed a triple positivity.7,8 In 
summary, the strict adherence to the ongoing recommended classification criteria allowed us to select a 
group of high-risk aPL and well-selected clinical profile APS patients. The aim of the Piedmont Consortium is 
to monitor them prospectively in an attempt to evaluate if current diagnostic and therapeutic strategies are 
really effective in this setting. More data from the prospective cohort will follow. 
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